Description medicines: Alfuzosin (Alfuzosin)
Amide N- [3 - [[4-amino-6,7-dimethoxy-2-quinazolinyl] methylamino] propyl] tetrahydro-furan-2-carboxylic acid hydrochloride.
Synonym: Dalfaz, Dalfaz.
On chemical structure similar to terazosin ( "open" piperazine ring).
Selectively blocking postsynaptic α1-adrenoceptors prostate, urethra, and the "triangle" of the bladder. The doses used in prostate hypertrophy, not significantly affect the vascular α1-adrenoceptors.
Bioavailability is 50%, C max - 3 h, T S - 8 hours; biotransformation in the liver, mainly with faeces as metabolites.
It is used mainly in the urological practice for the treatment of functional disorders of urination in patients with benign prostatic hyperplasia. Improves urination, reduce intraurethral pressure and resistance to current urine reduces dysuria.
The first dose (0.005 g - 1 tablet) administered at night (to avoid orthostatic effects), then - 1 tablet in the morning and at bedtime (not exceeding 0.01 g (10 mg) a day). Elderly patients are advised to take 1 tablet 1 time a day.
Precautions and adverse effects are the same as when using prazosin.
Product: tablets 0.0025 g (2.5 mg) and tablets retard 0.005 g (5 mg) (N. 14, 56) and 0.01 g (10 mg).